Abstract
A comparative study, using 5 antifungal drugs for the treatment of an experimental model of murine cryptococcosis, was carried out. One hundred and eighty Balb C mice, divided in 18 groups of 10 animals each, were intraperitoneally inoculated with 107 cells of Cryptococcus neoformans var. neoformans. Twelve groups were treated with different schedules beginning 5 days after inoculation, for 2 or 4 weeks.
The treatments were the following: amphotericin B (6 mg/kg/every other day, intraperitoneally); 5-fluorocytosine (300 mg/kg/day, by gavage); amphotericin B (6 mg/kg/every other day, intraperitoneally) in association with 5-fluorocytosine (300 mg/kg/day, by gavage); fluconazole, itraconazole and Sch 39.304 (all at the daily dose of 16 mg/kg, by gavage). The six remaining groups were used as controls and received the solvent for the drugs.
The evaluation of the efficacy of the different treatments was based on: survival time; macroscopy of brain, lungs, liver and spleen at autopsies; presence of encapsulated yeasts in microscopic examination of wet preparations of these organs; and cultures of a concentrated suspension of brain and lungs.
In the animals treated for 2 weeks, the combination of amphotericin B + 5-fluorocytosine was the most useful; it negativized the micro and macroscopic findings as well as 90% of the cultures, and prolonged the survival time up to 60 days.
Sixty per cent of the mice which received amphotericin B exhibited the same survival time and macroscopic findings as those treated with the association of amphotericin B + 5-fluorocytosine.
Among the azolic compounds, Sch 39.304 proved to be the most effective in the prolongation of survival time. None of the azoles showed differences with the control groups in the other parameters.
In the mice treated for 4 weeks, the only treatment that achieved the negativization of brain and lung cultures, was the combination of amphotericin B and 5-fluorocytosine. Amphotericin B alone was better than the azolic compounds, improving the macro and microscopic results and prolonging the survival time. Sch 39.304 produced the same survival time as amphotericin B, but did not determine the biological cure. The other azoles as well as 5-fluorocytosine showed a minor increase in survival time, with no modifications of the other parameters when compared with the controls. All the drugs applied showed better results when they were administered for 4 weeks.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
BavaA.J., IvannittiC. and NegroniR. (1989): Comparative study of four antifungal drugs in an experimental model of murine cryptococcosis -Mycopathologia 108: 81–88.
BavaA.J. and NegroniR. (1990): Estudio de 4 drogas antifungicas en un modelo experimental de criptococosis murina (2a. parte) - Revista Iberoamericana de Micología 7: 15–18.
BennettJ.E., DismukesW.E., DumaR.J.et al. (1979): The comparison of amphotericin B alone and combined with flucytosine in the treatment of cryptococcal meningitis - New England Journal of Medicine 301: 126–131.
CauwenbergG. and DeDoncherP. (1987): The clinical use of itraconazole in superficial and deep mycoses. In: Fromtling R.A.. Recent trends in the discovery, development and evaluation of antifungal agents - J.R. Prous Science Publishers - Barcelona pp. 273–284.
ChuckS.I. and SandeM.D. (1989): Infections with Cryptococcus neoformans in the acquired immunodeficiency syndrome - New England Journal of Medicine 321: 794–799.
CravenP.C., GraybillJ.R., JorgensenJ.H., DesmukesW.E. (1983): High dose of ketoconazole for treatment of fungal infections of the central nervous system -Annals of Internal Medicine 98: 160–167.
De Vita V.T., Hellman S. and Rosemberg S.A. (1986): En: SIDA, Etiologia, diagnóstico, tratamiento y prevención - Salvat Editores pp. 161–184.
DenningD.W., TuckerR.M., HansonL., HamiltonJ.R. and StevensD.A. (1989): Itraconazole therapy for cryptococcal meningitis and cryptococcosis -Archives of Internal Medicine 149: 2301–2308.
DrouhetE. and DupontB. (1990): Cryptococcosis. In: Jacobs P.H. and Nall L.. Antifungal drug therapy -Marcel Dekker Inc. - New York pp. 143–164.
Espinel-IngroffA., ShadomyS. and GebhartR.J. (1984): In vitro studies with R 51.211 (itraconazole) -Antimicrobial Agents & Chemotherapy 26: 5–9.
GraybillJ.R. (1987): Fluconazole efficacy in animal models of mycotic diseases. In: Fromtling R.A.. Recent trends in the discovery, development and evaluation of antifungal agents - J.R. Prous Science Publishers - Barcelona 284: 113–124.
GraybillJ.R. and ArheansJ.R. (1984): R 51.211 (raconazole) therapy of murine cryptococcosis -Sabouraudia 22: 445–453.
HayR.J. (1982): Clinical manifestations and management of cryptococcosis in the compromised patient. In: Warnock D.W. and Richardson M.D.. Fungal Infections in the compromised patient -Chapter 4. John Wiley & Sons, Ltd. Chichester -New York pp. 93–117.
KovacsJ.A., KovacsA.A., PolisM.et al. (1985): Cryptococcosis in the acquired immunodeficiency syndrome - Annals of Internal Medicine 103: 533–538.
LarsenR.A., LealM.A.E. and ChanL.S. (1990): Fluconazole compared with amphotericin B plus 5-flucytosine for cryptococcal meningitis in AIDS -Annals of Internal Medicine 113: 183–187.
NegroniR. (1990): Mitosis en pacientes con SIDA -Revista Argentina de Micologia 13: (1) 3–14.
RingelS. (1990): New antifungal agents for the systemic mycoses - Mycopathologia 109: 75–87.
RipponJ.W. (1988): Medical Mycology: The pathogenic Fungi and the pathogenic Actinomycetes -3rd Edition - W.B. Saunders - Philadelphia pp. 582–609.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Bava, A.J., Negroni, R. Comparative study of six antifungal treatments in an experimental model of murine cryptococcosis. Eur J Epidemiol 8, 422–426 (1992). https://doi.org/10.1007/BF00158577
Issue Date:
DOI: https://doi.org/10.1007/BF00158577